Related Experiment Videos

Perceived adherence to prescribed treatment in juvenile idiopathic arthritis over a one-year period

Debbie Ehrmann Feldman1, Mirella de Civita, Patricia L Dobkin

  • 1Université de Montréal, Montreal Children's Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. debbie.feldman@umontreal.ca

Arthritis and Rheumatism
|March 3, 2007
PubMed

Insights

Parental belief in treatment effectiveness is key for adherence in juvenile idiopathic arthritis (JIA). Higher perceived helpfulness of medications and exercises correlated with better adherence in children with JIA.

Area of Science:

  • Pediatric Rheumatology
  • Adolescent Medicine
  • Child Health Outcomes

Background:

  • Juvenile idiopathic arthritis (JIA) requires long-term treatment adherence for optimal management.
  • Understanding factors influencing adherence is crucial for improving patient outcomes.
  • Parental perception plays a significant role in a child's treatment adherence.

Purpose of the Study:

  • To assess perceived treatment adherence (medications and exercises) in JIA patients over one year.
  • To identify factors associated with parental perceived adherence to JIA treatment.

Main Methods:

  • Surveyed parents of 175 JIA patients across two Canadian children's hospitals.
  • Utilized the Parent Adherence Report Questionnaire (PARQ) with a 100-mm visual analog scale (VAS) every 3 months for 12 months.
  • Assessed parental coping, distress, child function, disease severity, and perceived treatment helpfulness.

Main Results:

  • Perceived medication adherence remained high (86-92%) throughout the year.
  • Perceived exercise adherence was lower (54-64%) but stable.
  • Higher adherence linked to perceived treatment helpfulness, lower disease severity, younger child age, and child involvement in treatment.

Conclusions:

  • Parental belief in the helpfulness of treatment is a significant factor in perceived adherence for JIA.
  • Targeting parental perceptions may enhance treatment adherence in pediatric arthritis management.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...